GoAI
Get started
DarioHealth Corp. logo

DarioHealth Corp.

DRIO

NASDAQHealthcareMedical - Specialties

Open in GoAI

Previous close

$7.49

+$0.32 · +4.46%

Aug 21, 4:00 PM ET

DRIO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

91

Deep Value

Momentum

24

Weakening

Sentiment

50

Mixed

Risk resilience

25

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
US
CEO
Erez Raphael
Listed since
Mar 14, 2016
Employees
163

Market position

Day range

Current $7.49

52-week range

Current $7.49

Open
$7.25
Previous close
$7.17
Volume
4.84K
0.31× average
Average volume
15.39K
Average daily volume
Market cap
54.76M USD
Beta
1.12
Market reference 1
50-day average
$7.1014
+5.47% above average
200-day average
$9.242
-18.96% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
10.86×
P/B (TTM)
1.27×
P/S (TTM)
2.61×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
56.09%
Operating margin
-328.83%
Net margin
322.77%

Financial health

Debt / equity
0.59×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends100%-73%-245%-417%Gross margin, FY2021: 39.34%Gross margin, FY2022: 34.91%Gross margin, FY2023: 29.40%Gross margin, FY2024: 49.06%Gross margin, FY2025: 56.64%Operating margin, FY2021: -372.90%Operating margin, FY2022: -205.42%Operating margin, FY2023: -276.09%Operating margin, FY2024: -213.55%Operating margin, FY2025: -163.94%Net margin, FY2021: -374.21%Net margin, FY2022: -224.88%Net margin, FY2023: -292.00%Net margin, FY2024: -158.09%Net margin, FY2025: -186.56%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 39.34%. Gross margin FY2022 34.91%. Gross margin FY2023 29.40%. Gross margin FY2024 49.06%. Gross margin FY2025 56.64%. Operating margin FY2021 -372.90%. Operating margin FY2022 -205.42%. Operating margin FY2023 -276.09%. Operating margin FY2024 -213.55%. Operating margin FY2025 -163.94%. Net margin FY2021 -374.21%. Net margin FY2022 -224.88%. Net margin FY2023 -292.00%. Net margin FY2024 -158.09%. Net margin FY2025 -186.56%.

Income trends

Revenue

22.36M USD-17.31%

Operating income

−36.66M USD+36.52%

Net income

−41.71M USD+2.42%
Income trends across reported periods38.1M USD−3.67M USD−45.44M USD−87.2M USDRevenue, FY2021: 20.51M USDRevenue, FY2022: 27.66M USDRevenue, FY2023: 20.35M USDRevenue, FY2024: 27.04M USDRevenue, FY2025: 22.36M USDOperating income, FY2021: −76.49M USDOperating income, FY2022: −56.81M USDOperating income, FY2023: −56.19M USDOperating income, FY2024: −57.74M USDOperating income, FY2025: −36.66M USDNet income, FY2021: −76.76M USDNet income, FY2022: −62.19M USDNet income, FY2023: −59.43M USDNet income, FY2024: −42.75M USDNet income, FY2025: −41.71M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 20.51M USD. Revenue FY2022 27.66M USD. Revenue FY2023 20.35M USD. Revenue FY2024 27.04M USD. Revenue FY2025 22.36M USD. Operating income FY2021 −76.49M USD. Operating income FY2022 −56.81M USD. Operating income FY2023 −56.19M USD. Operating income FY2024 −57.74M USD. Operating income FY2025 −36.66M USD. Net income FY2021 −76.76M USD. Net income FY2022 −62.19M USD. Net income FY2023 −59.43M USD. Net income FY2024 −42.75M USD. Net income FY2025 −41.71M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue22.36M USD27.04M USD20.35M USD27.66M USD20.51M USD
Cost of goods sold9.69M USD13.77M USD14.37M USD18M USD12.44M USD
Gross profit12.67M USD13.27M USD5.98M USD9.66M USD8.07M USD
Research and development13.79M USD24.18M USD20.25M USD19.65M USD17.22M USD
Selling, general, and administrative35.53M USD46.83M USD41.8M USD46.82M USD62.36M USD
Operating expenses49.32M USD71.01M USD62.17M USD66.47M USD84.56M USD
Interest income943K USD1.12M USD1.87M USD506K USD44K USD
Interest expense3.36M USD96K USD645K USD2.68M USD84K USD
Depreciation and amortization3.56M USD7.43M USD4.99M USD4.72M USD4.46M USD
Operating income−36.66M USD−57.74M USD−56.19M USD−56.81M USD−76.49M USD
Net income−41.71M USD−42.75M USD−59.43M USD−62.19M USD−76.76M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.81
FY2025
Latest fiscal-year revenue
22.36M USD
FY2025 · -17.31% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.35-1.91-3.46-5.02FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend28.39M25.46M22.54M19.62MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$12.50

66.89% upside
Past 12 months12-month forecastHigh $16.00Average $12.50Low $7.50

DRIO news

seekingalpha.com

DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript

DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

DarioHealth Q2 Earnings Call Highlights

DarioHealth NASDAQ: DRIO reported second-quarter 2026 revenue of $5.2 million, down from $5.6 million in the first quarter and $5.4 million a year earlier, as the company continued to shift away from pharmaceutical…

Read source
zacks.com

DarioHealth Corp. (DRIO) Reports Q2 Loss, Lags Revenue Estimates

DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $2.4 per share a year ago.

Read source
prnewswire.com

DarioHealth Reports Second Quarter 2026 Financial Results

Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business Gross margin increased to 62%, compared to 57% in the first quarter of 2026…

Read source
prnewswire.com

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care…

Read source
prnewswire.com

DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026

Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Aug. 3, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered…

Read source

DRIO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding DRIO

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
477.46K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
145.81K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Dimensional - US Sustainability Core 1 ETF logoDimensional - US Sustainability Core 1 ETFDFSU
Market value
5.6K
Weight
0.00%
AUM
2.35B USD
Expense ratio
0.15%
Price / 1D
$48.20+0.52%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
1.43K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%

Continue in GoAI

Research DRIO

research.disclaimer